Artal Group S.A. Atara Biotherapeutics, Inc. Transaction History

Artal Group S.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$8.44 - $16.89 $4.22 Million - $8.45 Million	-500,000 Reduced 33.33%	1,000,000 $9.29 Million
Q2 2021 Aug 13, 2021	SELL	$12.89 - $16.58 $6.45 Million - $8.29 Million	-500,000 Reduced 25.0%	1,500,000 $23.3 Million
Q1 2021 May 14, 2021	SELL	$14.0 - $20.72 $11.2 Million - $16.6 Million	-800,000 Reduced 28.57%	2,000,000 $28.7 Million
Q4 2020 Feb 11, 2021	BUY	$12.67 - $26.23 $6.97 Million - $14.4 Million	550,000 Added 24.44%	2,800,000 $55 Million
Q3 2020 Nov 13, 2020	SELL	$11.92 - $15.87 $2.98 Million - $3.97 Million	-250,000 Reduced 10.0%	2,250,000 $29.2 Million

Q1 2020 May 14, 2020	BUY	$5.69 - $17.78 $4.27 Million - $13.3 Million	750,000 Added 42.86%	2,500,000 $21.3 Million
Q4 2019 Feb 13, 2020	BUY	$10.89 - $16.79 $2.72 Million - $4.2 Million	250,000 Added 16.67%	1,750,000 $28.8 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $4.21 Million - $6.98 Million	350,000 Added 30.43%	1,500,000 $21.2 Million
Q1 2019 May 10, 2019	BUY	$28.4 - $41.74 $4.26 Million - $6.26 Million	150,000 Added 15.0%	1,150,000 $45.7 Million
Q2 2018 Aug 10, 2018	SELL	$35.15 - $51.45 $8.79 Million - $12.9 Million	-250,000 Reduced 20.0%	1,000,000 $36.8 Million
Q1 2018 May 10, 2018	BUY	$18.0 - $48.35 $4.5 Million - $12.1 Million	250,000 Added 25.0%	1,250,000 $48.8 Million
Q4 2017 Feb 09, 2018	BUY	$13.2 - $18.1 $5.28 Million - $7.24 Million	400,000 Added 66.67%	1,000,000 $18.1 Million
Q3 2017 Nov 08, 2017	BUY	$13.25 - $17.05 $7.95 Million - $10.2 Million	600,000	600,000 $9.93 Million

85M

18.4K

51.3K

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $781M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.